Please login to the form below

Not currently logged in
Email:
Password:

Vertex Pharma

This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.

Vertex continues upward trajectory with French Orkambi deal

Vertex continues upward trajectory with French Orkambi deal

The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor). ... Vertex has also submitted the triple

Latest news

More from news
Approximately 6 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... Meticulous preparations. The

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.

  • The Orkambi blame game The Orkambi blame game

    The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO ... NHS England accusing Vertex of being an“extreme outlier” and

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease

  • The challenges of making genomics a reality for patients today, not tomorrow The challenges of making genomics a reality for patients today, not tomorrow

    and higher risk science. The report singles out Vertex among a handful of successful biotech companies with highly innovative products. ... Dr Gillian Burgess is site head of UK Research and Vice President at Vertex.

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Vertex poaches new finance chief from Ironwood Pharmaceuticals Vertex poaches new finance chief from Ironwood Pharmaceuticals

    Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,

  • BMS appoints three independent directors BMS appoints three independent directors

    Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Frontera Group Frontera Group

    Dreamskin Health . Eusa Pharma. Galderma . Gedeon Richter. Genzyme. Grunenthal . Leukaemia UK. ... Novartis Pharmaceuticals. Novex Pharma. Pfizer. Shire Pharmaceuticals. UCB . Vertex Pharmaceuticals.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics